Loading…
Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer
Endometrial cancer (EnCa) ranks fourth in menace within women's malignant tumors. Large numbers of studies have proven that functional genes can change the process of tumors by regulating the cell cycle, thereby achieving the goal of targeted therapy. The transcriptional data of EnCa samples ob...
Saved in:
Published in: | Cancer cell international 2020-07, Vol.20 (1), p.329-329, Article 329 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3 |
---|---|
cites | cdi_FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3 |
container_end_page | 329 |
container_issue | 1 |
container_start_page | 329 |
container_title | Cancer cell international |
container_volume | 20 |
creator | Liu, Jinhui Mei, Jie Li, Siyue Wu, Zhipeng Zhang, Yan |
description | Endometrial cancer (EnCa) ranks fourth in menace within women's malignant tumors. Large numbers of studies have proven that functional genes can change the process of tumors by regulating the cell cycle, thereby achieving the goal of targeted therapy.
The transcriptional data of EnCa samples obtained from the TCGA database was analyzed. A battery of bioinformatics strategies, which included GSEA, Cox and LASSO regression analysis, establishment of a prognostic signature and a nomogram for overall survival (OS) assessment. The GEPIA and CPTAC analysis were applied to validate the dysregulation of hub genes. For mutation analysis, the "maftools" package was used.
GSEA identified that cell cycle was the most associated pathway to EnCa. Five cell cycle-related genes including HMGB3, EZH2, NOTCH2, UCK2 and ODF2 were identified as prognosis-related genes to build a prognostic signature. Based on this model, the EnCa patients could be divided into low- and high-risk groups, and patients with high-risk score exhibited poorer OS. Time-dependent ROC and Cox regression analyses revealed that the 5-gene signature could predict EnCa prognosis exactly and independently. GEPIA and CPTAC validation exhibited that these genes were notably dysregulated between EnCa and normal tissues. Lower mutation rates of PTEN, TTN, ARID1A, and etc. were found in samples with high-risk score compared with that with low-risk score. GSEA analysis suggested that the samples of the low- and high-risk groups were concentrated on various pathways, which accounted for the different oncogenic mechanisms in patients in two groups.
The current research construct a 5-gene signature to evaluate prognosis of EnCa patients, which may innovative clinical application of prognostic assessment. |
doi_str_mv | 10.1186/s12935-020-01428-z |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_54a098ad8c004d2aa421fb646256cf15</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_54a098ad8c004d2aa421fb646256cf15</doaj_id><sourcerecordid>2435246615</sourcerecordid><originalsourceid>FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3</originalsourceid><addsrcrecordid>eNpdksFu1DAQhiMEoqXwAhxQJC5cAvbEsZ0LEqoKVKrEBc7WxHayXiX2Yjuttk-Pu9tWLRePNfPPp5nRX1XvKflMqeRfEoW-7RoCpCGUgWxuX1SnlImuAcnFyyf_k-pNSltCqJCcvK5OWuB934E8rfYXKeMwu7RZrM91GGusfbi2c63tXJ69nm0T7YzZmnoXw-RDyk7XyU0e8xptSVrjdHZ-eqi7VDtf7zC7gkz1jcub2noTFpujwwJFr218W70acU723X08q_58v_h9_rO5-vXj8vzbVaO7XuRGcBQwjCAYw0EaNKbnBoSVoJk0LQGK0hAUkvYWaI-8HQA7S3mvh54WxVl1eeSagFu1i27BuFcBnTokQpwUxrLSbFXHkPQSjdSEMAOIDOg4cMah43qkXWF9PbJ267BYo8t-Eedn0OcV7zZqCtdKtAKkbAvg0z0ghr-rTVktLt1dGr0Na1LAgHetbAUt0o__Sbdhjb6cqqjaDhjnh4ngqNIxpBTt-DgMJerOJeroElVcog4uUbel6cPTNR5bHmzR_gM3T7tc</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2435246615</pqid></control><display><type>article</type><title>Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Liu, Jinhui ; Mei, Jie ; Li, Siyue ; Wu, Zhipeng ; Zhang, Yan</creator><creatorcontrib>Liu, Jinhui ; Mei, Jie ; Li, Siyue ; Wu, Zhipeng ; Zhang, Yan</creatorcontrib><description>Endometrial cancer (EnCa) ranks fourth in menace within women's malignant tumors. Large numbers of studies have proven that functional genes can change the process of tumors by regulating the cell cycle, thereby achieving the goal of targeted therapy.
The transcriptional data of EnCa samples obtained from the TCGA database was analyzed. A battery of bioinformatics strategies, which included GSEA, Cox and LASSO regression analysis, establishment of a prognostic signature and a nomogram for overall survival (OS) assessment. The GEPIA and CPTAC analysis were applied to validate the dysregulation of hub genes. For mutation analysis, the "maftools" package was used.
GSEA identified that cell cycle was the most associated pathway to EnCa. Five cell cycle-related genes including HMGB3, EZH2, NOTCH2, UCK2 and ODF2 were identified as prognosis-related genes to build a prognostic signature. Based on this model, the EnCa patients could be divided into low- and high-risk groups, and patients with high-risk score exhibited poorer OS. Time-dependent ROC and Cox regression analyses revealed that the 5-gene signature could predict EnCa prognosis exactly and independently. GEPIA and CPTAC validation exhibited that these genes were notably dysregulated between EnCa and normal tissues. Lower mutation rates of PTEN, TTN, ARID1A, and etc. were found in samples with high-risk score compared with that with low-risk score. GSEA analysis suggested that the samples of the low- and high-risk groups were concentrated on various pathways, which accounted for the different oncogenic mechanisms in patients in two groups.
The current research construct a 5-gene signature to evaluate prognosis of EnCa patients, which may innovative clinical application of prognostic assessment.</description><identifier>ISSN: 1475-2867</identifier><identifier>EISSN: 1475-2867</identifier><identifier>DOI: 10.1186/s12935-020-01428-z</identifier><identifier>PMID: 32699528</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Bioinformatics ; Cell cycle ; Childrens health ; Endometrial cancer ; Endometrium ; Genes ; GSEA ; Maternal & child health ; Medical prognosis ; Mutation ; Mutation rates ; Nomograms ; Patients ; Primary Research ; Prognosis ; Prognostic model ; PTEN protein ; Regression analysis ; Risk groups ; Software ; Survival analysis ; TCGA ; Transcription ; Tumors</subject><ispartof>Cancer cell international, 2020-07, Vol.20 (1), p.329-329, Article 329</ispartof><rights>The Author(s) 2020.</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3</citedby><cites>FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3</cites><orcidid>0000-0002-7983-8396</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372883/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2435246615?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32699528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Jinhui</creatorcontrib><creatorcontrib>Mei, Jie</creatorcontrib><creatorcontrib>Li, Siyue</creatorcontrib><creatorcontrib>Wu, Zhipeng</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><title>Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer</title><title>Cancer cell international</title><addtitle>Cancer Cell Int</addtitle><description>Endometrial cancer (EnCa) ranks fourth in menace within women's malignant tumors. Large numbers of studies have proven that functional genes can change the process of tumors by regulating the cell cycle, thereby achieving the goal of targeted therapy.
The transcriptional data of EnCa samples obtained from the TCGA database was analyzed. A battery of bioinformatics strategies, which included GSEA, Cox and LASSO regression analysis, establishment of a prognostic signature and a nomogram for overall survival (OS) assessment. The GEPIA and CPTAC analysis were applied to validate the dysregulation of hub genes. For mutation analysis, the "maftools" package was used.
GSEA identified that cell cycle was the most associated pathway to EnCa. Five cell cycle-related genes including HMGB3, EZH2, NOTCH2, UCK2 and ODF2 were identified as prognosis-related genes to build a prognostic signature. Based on this model, the EnCa patients could be divided into low- and high-risk groups, and patients with high-risk score exhibited poorer OS. Time-dependent ROC and Cox regression analyses revealed that the 5-gene signature could predict EnCa prognosis exactly and independently. GEPIA and CPTAC validation exhibited that these genes were notably dysregulated between EnCa and normal tissues. Lower mutation rates of PTEN, TTN, ARID1A, and etc. were found in samples with high-risk score compared with that with low-risk score. GSEA analysis suggested that the samples of the low- and high-risk groups were concentrated on various pathways, which accounted for the different oncogenic mechanisms in patients in two groups.
The current research construct a 5-gene signature to evaluate prognosis of EnCa patients, which may innovative clinical application of prognostic assessment.</description><subject>Bioinformatics</subject><subject>Cell cycle</subject><subject>Childrens health</subject><subject>Endometrial cancer</subject><subject>Endometrium</subject><subject>Genes</subject><subject>GSEA</subject><subject>Maternal & child health</subject><subject>Medical prognosis</subject><subject>Mutation</subject><subject>Mutation rates</subject><subject>Nomograms</subject><subject>Patients</subject><subject>Primary Research</subject><subject>Prognosis</subject><subject>Prognostic model</subject><subject>PTEN protein</subject><subject>Regression analysis</subject><subject>Risk groups</subject><subject>Software</subject><subject>Survival analysis</subject><subject>TCGA</subject><subject>Transcription</subject><subject>Tumors</subject><issn>1475-2867</issn><issn>1475-2867</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdksFu1DAQhiMEoqXwAhxQJC5cAvbEsZ0LEqoKVKrEBc7WxHayXiX2Yjuttk-Pu9tWLRePNfPPp5nRX1XvKflMqeRfEoW-7RoCpCGUgWxuX1SnlImuAcnFyyf_k-pNSltCqJCcvK5OWuB934E8rfYXKeMwu7RZrM91GGusfbi2c63tXJ69nm0T7YzZmnoXw-RDyk7XyU0e8xptSVrjdHZ-eqi7VDtf7zC7gkz1jcub2noTFpujwwJFr218W70acU723X08q_58v_h9_rO5-vXj8vzbVaO7XuRGcBQwjCAYw0EaNKbnBoSVoJk0LQGK0hAUkvYWaI-8HQA7S3mvh54WxVl1eeSagFu1i27BuFcBnTokQpwUxrLSbFXHkPQSjdSEMAOIDOg4cMah43qkXWF9PbJ267BYo8t-Eedn0OcV7zZqCtdKtAKkbAvg0z0ghr-rTVktLt1dGr0Na1LAgHetbAUt0o__Sbdhjb6cqqjaDhjnh4ngqNIxpBTt-DgMJerOJeroElVcog4uUbel6cPTNR5bHmzR_gM3T7tc</recordid><startdate>20200720</startdate><enddate>20200720</enddate><creator>Liu, Jinhui</creator><creator>Mei, Jie</creator><creator>Li, Siyue</creator><creator>Wu, Zhipeng</creator><creator>Zhang, Yan</creator><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7983-8396</orcidid></search><sort><creationdate>20200720</creationdate><title>Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer</title><author>Liu, Jinhui ; Mei, Jie ; Li, Siyue ; Wu, Zhipeng ; Zhang, Yan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Bioinformatics</topic><topic>Cell cycle</topic><topic>Childrens health</topic><topic>Endometrial cancer</topic><topic>Endometrium</topic><topic>Genes</topic><topic>GSEA</topic><topic>Maternal & child health</topic><topic>Medical prognosis</topic><topic>Mutation</topic><topic>Mutation rates</topic><topic>Nomograms</topic><topic>Patients</topic><topic>Primary Research</topic><topic>Prognosis</topic><topic>Prognostic model</topic><topic>PTEN protein</topic><topic>Regression analysis</topic><topic>Risk groups</topic><topic>Software</topic><topic>Survival analysis</topic><topic>TCGA</topic><topic>Transcription</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Jinhui</creatorcontrib><creatorcontrib>Mei, Jie</creatorcontrib><creatorcontrib>Li, Siyue</creatorcontrib><creatorcontrib>Wu, Zhipeng</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Cancer cell international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Jinhui</au><au>Mei, Jie</au><au>Li, Siyue</au><au>Wu, Zhipeng</au><au>Zhang, Yan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer</atitle><jtitle>Cancer cell international</jtitle><addtitle>Cancer Cell Int</addtitle><date>2020-07-20</date><risdate>2020</risdate><volume>20</volume><issue>1</issue><spage>329</spage><epage>329</epage><pages>329-329</pages><artnum>329</artnum><issn>1475-2867</issn><eissn>1475-2867</eissn><abstract>Endometrial cancer (EnCa) ranks fourth in menace within women's malignant tumors. Large numbers of studies have proven that functional genes can change the process of tumors by regulating the cell cycle, thereby achieving the goal of targeted therapy.
The transcriptional data of EnCa samples obtained from the TCGA database was analyzed. A battery of bioinformatics strategies, which included GSEA, Cox and LASSO regression analysis, establishment of a prognostic signature and a nomogram for overall survival (OS) assessment. The GEPIA and CPTAC analysis were applied to validate the dysregulation of hub genes. For mutation analysis, the "maftools" package was used.
GSEA identified that cell cycle was the most associated pathway to EnCa. Five cell cycle-related genes including HMGB3, EZH2, NOTCH2, UCK2 and ODF2 were identified as prognosis-related genes to build a prognostic signature. Based on this model, the EnCa patients could be divided into low- and high-risk groups, and patients with high-risk score exhibited poorer OS. Time-dependent ROC and Cox regression analyses revealed that the 5-gene signature could predict EnCa prognosis exactly and independently. GEPIA and CPTAC validation exhibited that these genes were notably dysregulated between EnCa and normal tissues. Lower mutation rates of PTEN, TTN, ARID1A, and etc. were found in samples with high-risk score compared with that with low-risk score. GSEA analysis suggested that the samples of the low- and high-risk groups were concentrated on various pathways, which accounted for the different oncogenic mechanisms in patients in two groups.
The current research construct a 5-gene signature to evaluate prognosis of EnCa patients, which may innovative clinical application of prognostic assessment.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>32699528</pmid><doi>10.1186/s12935-020-01428-z</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7983-8396</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1475-2867 |
ispartof | Cancer cell international, 2020-07, Vol.20 (1), p.329-329, Article 329 |
issn | 1475-2867 1475-2867 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_54a098ad8c004d2aa421fb646256cf15 |
source | Open Access: PubMed Central; Publicly Available Content Database |
subjects | Bioinformatics Cell cycle Childrens health Endometrial cancer Endometrium Genes GSEA Maternal & child health Medical prognosis Mutation Mutation rates Nomograms Patients Primary Research Prognosis Prognostic model PTEN protein Regression analysis Risk groups Software Survival analysis TCGA Transcription Tumors |
title | Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T05%3A42%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Establishment%20of%20a%20novel%20cell%20cycle-related%20prognostic%20signature%20predicting%20prognosis%20in%20patients%20with%20endometrial%20cancer&rft.jtitle=Cancer%20cell%20international&rft.au=Liu,%20Jinhui&rft.date=2020-07-20&rft.volume=20&rft.issue=1&rft.spage=329&rft.epage=329&rft.pages=329-329&rft.artnum=329&rft.issn=1475-2867&rft.eissn=1475-2867&rft_id=info:doi/10.1186/s12935-020-01428-z&rft_dat=%3Cproquest_doaj_%3E2435246615%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2435246615&rft_id=info:pmid/32699528&rfr_iscdi=true |